Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C. [electronic resource]
Producer: 20101026Description: G726-34 p. digitalISSN:- 1522-1547
- Adaptor Proteins, Signal Transducing
- Adaptor Proteins, Vesicular Transport -- genetics
- Administration, Oral
- Angiotensin II Type 1 Receptor Blockers -- administration & dosage
- Biopsy, Needle
- Collagen -- genetics
- Down-Regulation
- Female
- Gene Expression Regulation, Enzymologic -- drug effects
- Hepatitis C, Chronic -- complications
- Humans
- Inflammation Mediators -- metabolism
- Liver -- drug effects
- Liver Cirrhosis -- drug therapy
- Losartan -- administration & dosage
- Male
- Matrix Metalloproteinase 2 -- genetics
- Middle Aged
- NADPH Oxidases -- genetics
- Reverse Transcriptase Polymerase Chain Reaction
- Severity of Illness Index
- Spain
- Time Factors
- Treatment Outcome
- Urokinase-Type Plasminogen Activator -- genetics
- rac1 GTP-Binding Protein -- genetics
No physical items for this record
Publication Type: Clinical Trial, Phase IV; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.